Ausgabe 5/2019
Inhalt (21 Artikel)
The thioredoxin system and cancer therapy: a review
Fariba Mohammadi, Arash Soltani, Atefeh Ghahremanloo, Hossein Javid, Seyed Isaac Hashemy
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review
Inthuorn Kulma, Kanyarat Boonprasert, Kesara Na-Bangchang
Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients
Silpa Nuthalapati, Sven Stodtmann, Stacie Peacock Shepherd, Christine K. Ratajczak, Sven Mensing, Rajeev Menon, Hao Xiong
Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma
Yuto Yamada, Yuta Ohno, Yu Kato, Ryo Kobayashi, Hideki Hayashi, Shiho Miyahara, Keita Nakane, Kosuke Mizutani, Shigeaki Yokoi, Hironori Fujii, Hirotoshi Iihara, Takuma Ishihara, Takashi Deguchi, Tadashi Sugiyama, Akio Suzuki
Population pharmacokinetics of siltuximab: impact of disease state
Mina Nikanjam, Jin Yang, Edmund V. Capparelli
Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer
Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, Teresa Macarulla, Valeria Merz, Timothy H. Waterhouse, Colin Miles, Michael M. Lahn, Ann Cleverly, Karim A. Benhadji
Evaluation of the potential for QTc prolongation with avelumab
Yulia Vugmeyster, Gülseren Güzel, Meliessa Hennessy, Anja H. Loos, Haiqing Dai
Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma
K. Yamazaki, T. Doi, M. Ikeda, T. Okusaka, A. Schueler, M. Watanabe, A. Ohtsu
Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab
Baoquan Liu, Fei Su, Xiaohong Lv, Wenbo Zhang, Xiaochen Shang, Yafang Zhang, Jianguo Zhang
Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan
Mayu Yunokawa, Shinsuke Sasada, Yae Takehara, Kenta Takahashi, Tatsunori Shimoi, Kan Yonemori, Mitsuya Ishikawa, Tomoyasu Kato, Kenji Tamura
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer
Midori Shimada, Hiroyuki Yamaguchi, Minoru Fukuda, Hiromi Tomono, Noritaka Honda, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takaya Ikeda, Katsumi Nakatomi, Yoichi Nakamura, Seiji Nagashima, Takuya Yamazaki, Hiroshi Mukae
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients
Tetsuo Tani, Katsuhiko Naoki, Hiroyuki Yasuda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Hideki Terai, Shinnosuke Ikemura, Takashi Sato, Kenzo Soejima
Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice
Jim H. Hughes, Richard N. Upton, Stephanie E. Reuter, Darlene M. Rozewski, Mitch A. Phelps, David J. R. Foster
Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer
Gerardo Rosati, Raffaele Addeo, Giuseppe Aprile, Antonio Avallone, Domenico Bilancia, Silvia Brugnatelli, Gabriella Buccafusca, Chiara Carlomagno, Stefano Cordio, Sara Delfanti, Emanuela Dell’Aquila, Maurizio Di Bisceglie, Samantha Di Donato, Antonio Di Stasi, Domenico Germano, Francesco Giuliani, Cristina Granetto, Tiziana Pia Latiano, Silvana Leo, Paolo Tralongo, Maria Elena Stroppolo, Filippo Venturini, Salvatore Bianco
Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases
Kazuyo Shimada, Shiori Hasegawa, Satoshi Nakao, Ririka Mukai, Kiyoka Matsumoto, Mizuki Tanaka, Hiroaki Uranishi, Mayuko Masuta, Shohei Nishida, Shinya Shimizu, Yuichi Hayashi, Akio Suzuki, Mitsuhiro Nakamura
Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study
Takumi Sakurada, Sanako Bando, Yoshito Zamami, Kenshi Takechi, Masayuki Chuma, Mitsuhiro Goda, Yasushi Kirino, Toshimi Nakamura, Kazuhiko Teraoka, Masami Morimoto, Akira Tangoku, Keisuke Ishizawa
A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer
Saichun Qi, Ya Mao, Mingjun Jiang
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects
Kiana Keyvanjah, Blaire Cooke, David Martin, Daniel Di Primeo, Laura Sterling, Jane Liang, Elizabeth Olek, Igor Rubets, Alvin Wong
Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment
Yanan Sun, Lingyan Yan, Jihua Guo, Jun Shao, Rong Jia
A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies
Filipa Lynce, Hongkun Wang, Emanuel F. Petricoin, Paula R. Pohlmann, Brandon Smaglo, Jimmy Hwang, Aiwu R. He, Deepa S. Subramaniam, John Deeken, John Marshall, Michael J. Pishvaian